Myocyte Enhancer Factor 2D (MEF2D) is a critical transcription factor belonging to the MADS-box family. While historically studied in muscle development and neuroprotection, MEF2D has emerged as a high-value oncogenic driver, particularly in pediatric acute lymphoblastic leukemia (ALL) through oncogenic fusions (e.g., MEF2D-BCL9, MEF2D-HNRNPUL1) and in solid tumors via transcriptional dysregulation. Developing therapeutics targeting this intracellular transcription factor requires robust assay systems to validate protein-protein interactions (PPI) and gene transcription modulation.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for MEF2D drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | MEF2D Recombinant Protein (MADS-box domain / Full Length) High purity (>95%), Endotoxin controlled. Sequence Verified. |
View MEF2D Products |
| Gene Delivery | MEF2D Promise-ORF / Lentivirus Full-length ORF and fusion variant constructs for stable cell line generation. |
View MEF2D Products |
| Benchmark Ab | Anti-MEF2D Recombinant Antibody Sequence-verified positive control for Western Blot, ChIP, and IP assays. |
View MEF2D Products |
| Validator | MEF2D siRNA Set Target-specific knockdown verification in cancer cell lines. |
View MEF2D Products |
| Related Target A | HDAC4 Class IIa histone deacetylase that interacts directly with MEF2D to repress transcription. |
View HDAC4 Products |
| Related Target B | EP300 Histone acetyltransferase (p300) acting as a co-activator for MEF2D-mediated transcription. |
View EP300 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Intracellular PPI Screening (MEF2D-HDAC4/p300) | Highly purified, native-conformation recombinant proteins verified by SDS-PAGE and Mass Spectrometry. |
| MEF2 Family Subfamily Counter-Screening | Homolog panel (MEF2A, MEF2B, MEF2C) available with strict sequence validation to ensure off-target selectivity. |
| Lack of Controls for Fusion Variants | Custom Lentiviral vectors for specific clinical fusion variants (e.g., MEF2D-BCL9) sequence-verified. |
| False Positives in Transcription Assays | Validated siRNA knockout pools included to confirm target-specific transcriptional rescue. |
Live MEF2D R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of MEF2D is transitioning from academic validation to active drug discovery. Because MEF2D is an intracellular transcription factor, traditional monoclonal antibody approaches are inapplicable. Instead, the landscape is dominated by small-molecule inhibitors disrupting protein-protein interactions (such as the MEF2D-HDAC4 or MEF2D-p300 interface) and targeted protein degraders (PROTACs). As structural biology resolves the exact binding pockets of the MADS-box and MEF2 domains, the next wave of R&D is focusing on allele-specific degradation of oncogenic MEF2D fusion proteins in leukemia.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule PPI | Academic Consortia / Biotech | Acute Lymphoblastic Leukemia (ALL) | Binding affinity assays (Requires high-purity MEF2D MADS-box domain protein) |
| PROTAC (Degrader) | Oncology-focused Biopharma | Solid Tumors (Hepatocellular, Breast) | Degradation kinetics (Need sequence-verified Lentivirus for stable reporter lines) |
| siRNA / RNAi | RNA Therapeutics Developers | Neurodegenerative Diseases | In vitro knockdown validation (Need validated siRNA positive controls) |